MNG123
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.328
- CHOLESTEROL_HOMEOSTASIS+0.323
- PEROXISOME+0.279
- ADIPOGENESIS+0.230
- HEME_METABOLISM+0.215
- NOTCH_SIGNALING+0.192
- WNT_BETA_CATENIN_SIGNALING+0.188
- HEDGEHOG_SIGNALING+0.171
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.169
- BILE_ACID_METABOLISM+0.142
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.496
- IL6_JAK_STAT3_SIGNALING-0.450
- G2M_CHECKPOINT-0.418
- ANGIOGENESIS-0.417
- E2F_TARGETS-0.403
- INFLAMMATORY_RESPONSE-0.403
- ALLOGRAFT_REJECTION-0.384
- INTERFERON_GAMMA_RESPONSE-0.353
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.331
- KRAS_SIGNALING_UP-0.329
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG108 | — | — | 0.852 |
| 2 | MDT-AP-0364 | Med | Medulloblastoma | 0.824 |
| 3 | MNG682 | — | — | 0.818 |
| 4 | MDT-AP-0402 | Med | Medulloblastoma | 0.816 |
| 5 | D155B4CA-927F-4B4F-B6BC-2D41267F195E | — | — | 0.805 |
| 6 | aMVAC.P_001_TURBT_S217 | — | — | 0.803 |
| 7 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.802 |
| 8 | 68fda9a5-c6eb-4445-91f7-bd0078080b9d | — | — | 0.800 |
| 9 | SRR1320873 | GTEX | — | 0.798 |
| 10 | TCGA-86-8281-01A-11R-2287-07 | — | cohortA2 | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.328 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.323 | Remibrutinib | — uncovered |
| PEROXISOME | 0.279 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.215 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.192 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.188 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.171 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.169 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.142 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.105 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.076 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.027 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.017 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.013 | Inavolisib | — uncovered |
| MYOGENESIS | 0.006 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.003 | Inavolisib | — uncovered |